Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Tausend

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Dermatology Online Journal|January 25, 2014
Primary amyloidosis-induced nail dystrophyWilliam Tausend, Megan Neill, Brent Kelly
Journal of Cutaneous Medicine and Surgery|May 8, 2014
Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumabWilliam Tausend, Christopher Downing, Stephen Tyring
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Dermatology Online Journal|January 25, 2014
Primary amyloidosis-induced nail dystrophyWilliam Tausend, Megan Neill, Brent Kelly
Journal of Cutaneous Medicine and Surgery|May 8, 2014
Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumabWilliam Tausend, Christopher Downing, Stephen Tyring
Pageof 1